Wellcome Leap
Wellcome Leap is a US 501(c)(3) nonprofit that operates as a "global ARPA for health," funding 16 bold $45-60M research programs across 30 countries and a 170-institution network to accelerate health breakthroughs in 5-10 years.
- Company typePrivate
- Founded2020
- HeadquartersLos Angeles, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Wellcome Leap does
Wellcome Leap Inc. is a US 501(c)(3) nonprofit research funding organization founded in 2020 by the Wellcome Trust with $300 million in initial grant capital, incorporated in San Diego. It operates as a "global ARPA for health," applying the DARPA program-management model — bold targets, tight timelines, multi-disciplinary teams, results-based program termination — to complex human-health problems. Core operations consist of designing, funding, and executing a portfolio of 16 thematic programs (e.g., Q4Bio quantum computing for biology, HOPE bioengineered organs, Dynamic Resilience healthy aging, VISIBLE and The Missed Vital Sign in women's health, Resistance Networks in antimicrobial resistance) typically funded at $45-60M each and structured for 3-5 year delivery against audacious goals such as reducing stillbirths by half or achieving quantum advantage for drug discovery.
Execution runs through the proprietary Health Breakthrough Network (HBNet), a standardized research network of 170+ institutions across six continents representing more than 1,500,000 researchers. HBNet is enabled by Master Academic Research Funding Agreements (MARFA/CORFA) that allow funded projects to begin in days rather than the 6-12 months typical of academic grant administration. Programs are steered by dedicated Program Directors, several drawn from institutions such as Oxford, Cambridge, and Idorsia Pharmaceuticals, and supported by an in-house leadership team with deep operational pedigree (former DARPA Director, former Illumina CEO, former Goldman Sachs Vice Chairman).
The revenue model is philanthropic rather than commercial: Wellcome Leap receives grant funding from its founding parent the Wellcome Trust and a growing set of co-funding strategic partners including Pivotal Ventures ($100M for women's health), Temasek Trust ($60M for Dynamic Resilience), Bayer ($50M for Resistance Networks), and IBM Quantum (in-kind hardware for Q4Bio). It does not sell products or services, does not license technology for revenue, and does not publicly disclose annual receipts. Target "customers" are the research institutions, biotech firms, and clinical partners that compete for program funding and use HBNet as a collaboration backbone.
Wellcome Leap firmographics
Firmographics- Name
- Wellcome Leap
- Legal name
- Wellcome Leap Inc.
- Website
- https://wellcomeleap.org
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Wellcome Leap is a US 501(c)(3) nonprofit that operates as a "global ARPA for health," funding 16 bold $45-60M research programs across 30 countries and a 170-institution network to accelerate health breakthroughs in 5-10 years.
- Ownership category
- akta.pro rank
Wellcome Leap industry classification
Industry- Product category
- Health Research Funding
- NAICS
- Voluntary Health Organizations (813212), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731), Services-Social Services (8300), Services-Health Services (8000)
- akta.pro primary industry
- Health & Medical Research Grantmaking Foundations (BPAGAKAL)
- akta.pro secondary industries
- Global Health Research, Clinical Trials & Product Development Partnerships (PDPs) (HLAJAOAM), Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS) (BPAGACAA)
Keywords
Where Wellcome Leap is headquartered
LocationHeadquarters
- HQ city
- Los Angeles
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Wellcome Leap business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Revenue model
- Philanthropic Grant Funding: Wellcome Leap is a non-profit organization funded by the Wellcome Trust and other strategic partners. The organization deploys grant funding to accelerate health breakthroughs through unconventional programs executed at scale. Initial funding of $300 million was provided by the Wellcome Trust in 2020.
- Co-Funded Programs: Strategic partnerships where co-funding partners co-invest in specific programs. Examples include: $55M VISIBLE program with Pivotal, $60M Dynamic Resilience with Temasek Trust, $50M Resistance Networks with Bayer, and $100M women's health partnership with Pivotal Ventures.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels6 records
Wellcome Leap product offering
Product offeringCore offering
Wellcome Leap is a US 501(c)(3) nonprofit that builds and executes bold, unconventional health research programs funded at scale ($45-60M each), applying a DARPA-inspired innovation model to accelerate breakthroughs in human health over 5-10 year timelines. The organization runs 16 programs across 30 countries — including Q4Bio (quantum computing for biology), HOPE (bioengineered organs), Dynamic Resilience (healthy aging), and women's health programs (VISIBLE, The Missed Vital Sign, In Utero, CARE) — coordinated through the Health Breakthrough Network of 170+ research institutions representing 1.5 million researchers.
Product overview
Wellcome Leap is a billion-dollar breakthrough engine for human health operating as a global ARPA-style funding model. The organization builds and executes bold, unconventional programs funded at scale, targeting complex human health challenges with the goal of achieving breakthrough scientific and technological solutions in years, not decades. The portfolio consists of 16 distinct research programs across diverse health areas including quantum computing for biology (Q4Bio), healthy aging and resilience (Dynamic Resilience), organ engineering (HOPE), women's health (VISIBLE, The Missed Vital Sign, In Utero, CARE), addiction treatment, infectious disease preparedness (R3 Global), and various other therapeutic areas. These programs are supported by the Health Breakthrough Network (HBNet), the world's largest research network spanning 170+ institutions across six continents. Programs range from $45M to $60M in funding and operate over 3-5 year timelines with ambitious goals such as eliminating dialysis, reducing stillbirths by half, or achieving quantum advantage for drug discovery.
Differentiator
Problem solved
Functional benefit
Brands
- Leap Health Breakthrough Network (HBNet): The world's largest research network dedicated to accelerating breakthroughs in human health, with over 170 organizations on 6 continents representing more than 1,500,000 researchers.
Products and services
- Q4Bio (Quantum for Bio) A $50 million supported challenge program that brought together quantum software, hardware, and biology experts to develop algorithms demonstrating quantum advantage for health applications. The program culminated in Algorithmiq winning $2M for an end-to-end quantum-classical workflow simulating photodynamic cancer therapy drugs.
- Dynamic Resilience A $60 million program jointly funded with Temasek Trust focused on identifying and validating causal measures and models of health resilience with predictive value sufficient to make clinical decisions and support development of preventative interventions for healthy aging.
- HOPE (Human Organs, Physiology, and Engineering)
Quantifiable outcome
- 90% of treatments succeed in animal studies but fail in humans — Wellcome Leap programs aim to transform preclinical prediction
- +3 more outcomes
Companies that use Wellcome Leap
Customer profileNamed customers6 records
Segments3 records
Ideal customer profiles3 records
Wellcome Leap technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Wellcome Leap partnerships and signals
Strategic signalPartnerships
13 partnerships are on record, tiered core and flagship.
- The Menopause SocietycorePartner in Melinda French Gates' $215M women's health commitment alongside Wellcome Leap, focusing on access to care during reproductive years, midlife, menopause, and mental health.
- World Economic ForumcoreCollaborated on Women's Health Innovation Radar report identifying systemic gaps in R&D funding — only 20% of research funding is women-focused, women-focused research accounts for 16% of publications and fewer than 3% of clinical trials.
- Kearney Health InstitutecorePartnered with World Economic Forum and Wellcome Leap on Women's Health Innovation Radar report analyzing R&D investment patterns from 2016-2025 for 10 high-impact conditions.
- Bill & Melinda Gates FoundationcoreCollaborated on Women's Health Innovation Radar report identifying allocation gap, evidence gap, and translation gap in women's health R&D funding.
- IBM QuantumcoreIBM provided quantum computing hardware support for the Q4Bio challenge program. Five of six Phase III finalist teams used IBM quantum hardware for research spanning drug discovery, genomics, and biomarker discovery, utilizing 100+ qubit processors with circuit depths of 1,000 to 10,000 gates.
- Cleveland CliniccoreCleveland Clinic provided biological expertise for the Q4Bio challenge, collaborating with Algorithmiq and IBM to demonstrate scalable quantum algorithms for photodynamic therapy simulation in cancer treatment.
- AlgorithmiqcoreHelsinki-based quantum computing startup won the $2 million Phase III prize in Q4Bio for demonstrating an end-to-end quantum-classical workflow for drug discovery on real quantum hardware, simulating activation pathways of a photosensitiser cancer drug.
- University of OxfordcoreResearchers encoded the complete genome of hepatitis D virus onto an IBM 156-qubit quantum processor — first-ever complete genome loaded onto a quantum computer — as part of Q4Bio Quantum Pangenome project.
- Wellcome Sanger InstitutecoreContributed to Quantum Pangenome project under Q4Bio, encoding complete hepatitis D virus genome onto quantum processor to demonstrate quantum computing potential for genomic analysis.
- InfleqtioncoreSelected to advance to Phase 3 of Q4Bio challenge, collaborating with University of Chicago and MIT on applying hybrid quantum-classical workflows to forecast treatment response in head-and-neck cancer using clinical data.
- Medicines360corePartnership to accelerate development and access to new lifesaving pregnancy and stillbirth risk-reduction tools for women worldwide, announced January 2026.
- Pivotal VenturesflagshipHistoric $100 million partnership between Wellcome Leap and Pivotal Ventures (Melinda French Gates organization) to advance women's health research through innovative programs. The partnership focuses on cardiovascular, autoimmune, and mental health issues affecting women, with a grant process inspired by DARPA aiming to generate significant health improvements within three to five years. Total commitment to women's health now exceeds $250M.
- Spark BiomedicalcoreAwarded funding from Wellcome Leap for The Missed Vital Sign women's health initiative, supporting clinical trials of transcutaneous auricular neurostimulation (tAN) platform for heavy menstrual bleeding, including women with von Willebrand Disease.
Scale indicators8 records
Recent moves8 records
Expansion highlights6 records
Wellcome Leap competitors and assessment
Company assessmentDirect peers
- ARPA-H: U.S. federal Advanced Research Projects Agency for Health, launched 2022 to apply ARPA-style program management to biomedical breakthroughs. Most direct comparable as both organizations explicitly apply the DARPA model to human health with similar program structures and timelines.
- Coalition for Epidemic Preparedness Innovations (CEPI): Global partnership that accelerates development of vaccines against epidemic threats. Comparable as a multi-funder, mission-driven organization funding coordinated global research programs toward specific health breakthroughs with defined timelines.
- Foundation for the National Institutes of Health (FNIH): Nonprofit that manages public-private partnerships supporting NIH mission areas, often with multi-million-dollar multi-stakeholder programs. Comparable as a non-governmental entity orchestrating large-scale biomedical research programs across institutions.
Broad incumbents
- Howard Hughes Medical Institute (HHMI): Major biomedical research organization funding investigator-initiated science across U.S. universities. Comparable in scale and ambition for breakthrough science, but uses a sustained-investigator model rather than DARPA-style time-bound programs.
- Chan Zuckerberg Initiative (CZI): Philanthropic initiative of Mark Zuckerberg and Priscilla Chan with substantial biomedical research funding including the Chan Zuckerberg Biohub network. Comparable as a large-scale private science funder focused on ambitious long-horizon health challenges.
- Gates Foundation: Bill & Melinda Gates Foundation is one of the largest global health funders, with explicit collaboration with Wellcome Leap on the Women's Health Innovation Radar report. Comparable as a massive-scale philanthropic health R&D funder with global program reach.
- Wellcome Trust: Wellcome Leap's parent foundation, one of the world's largest charitable foundations focused on health research. Directly comparable as a global health research funder, and Wellcome Leap was created to apply a different (DARPA-style) operating model on top of the parent organization's traditional funding approach.
- Novo Nordisk Foundation: Major Danish philanthropic foundation funding biomedical research, biotechnology, and innovation at significant scale. Comparable as a large European foundation making multi-year, multi-hundred-million-dollar bets on health breakthroughs.
Emerging players
- Schmidt Futures: Philanthropic initiative of Eric and Wendy Schmidt funding ambitious science and technology programs. Comparable as a newer-generation philanthropic funder focused on breakthrough research with unconventional program structures.
Regional players
- BARDA (Biomedical Advanced Research and Development Authority): U.S. government agency within HHS that funds development of medical countermeasures. Comparable in funding advanced translational R&D at scale, but primarily U.S.-focused and government-operated rather than philanthropic.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
Wellcome Leap social profiles
Digital presenceWellcome Leap financial estimates
Financial estimateRevenue estimate
Valuation estimate
Wellcome Leap leadership team
Management profileNumber of profiles
Profiles22 records
Wellcome Leap funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Wellcome Leap M&A and investment
M&A and investmentM&A
Investments6 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Wellcome Leap
What does Wellcome Leap do?
Wellcome Leap is a US 501(c)(3) nonprofit that builds and executes bold, unconventional health research programs funded at scale ($45-60M each), applying a DARPA-inspired innovation model to accelerate breakthroughs in human health over 5-10 year timelines. The organization runs 16 programs across 30 countries — including Q4Bio (quantum computing for biology), HOPE (bioengineered organs), Dynamic Resilience (healthy aging), and women's health programs (VISIBLE, The Missed Vital Sign, In Utero, CARE) — coordinated through the Health Breakthrough Network of 170+ research institutions representing 1.5 million researchers.
Is Wellcome Leap a public or private company?
Wellcome Leap is a private company. It is classified as nonprofit foundation owned and is currently operating.
When was Wellcome Leap founded?
Wellcome Leap was founded in 2020. It employs 1 to 10 people.
Where is Wellcome Leap based?
Wellcome Leap is headquartered in Los Angeles, United States, in the North America region.
How does Wellcome Leap make money?
Two revenue lines are on record. Philanthropic Grant Funding is the primary driver. The others are co-Funded Programs.
Who are Wellcome Leap's main competitors?
Direct peers on record are ARPA-H, Coalition for Epidemic Preparedness Innovations (CEPI) and Foundation for the National Institutes of Health (FNIH). Broad incumbents are Howard Hughes Medical Institute (HHMI), Chan Zuckerberg Initiative (CZI), Gates Foundation, Wellcome Trust and Novo Nordisk Foundation. Schmidt Futures is listed as an emerging player. BARDA (Biomedical Advanced Research and Development Authority) is listed as a regional player.
Does Wellcome Leap have an API?
No public API is recorded for Wellcome Leap.
What industry is Wellcome Leap in?
Wellcome Leap's product category is Health Research Funding. Its primary akta.pro industry code is BPAGAKAL, Health & Medical Research Grantmaking Foundations, with a secondary code of HLAJAOAM, Global Health Research, Clinical Trials & Product Development Partnerships (PDPs). Its NAICS code is 813212 and its SIC code is 8731.